Background: This protocol of systematic review aims to investigate the effectiveness of electrical stimulation (ES) on adverse events (AEs) caused by chemotherapy in patients with cervical cancer (CC).
Introduction
Cervical cancer (CC) is one of the most common female malignancies and is also one of the leading causes of mortality in females worldwide. [1] [2] [3] The previous study reported that there were 527,600 new CC cases and 265,700 deaths in females worldwide in 2012. [4] In China, there were about 98,900 new CC cases in 2015. It accounted for 18.7% of the global incidence of CC among the female population. [5] Several risk factors can result in CC, such as many sexual partners, early sexual activity, other sexually transmitted infections, a weak immune system, and smoking. [6] [7] [8] Currently available managements mainly include chemotherapy, radiotherapy, and surgery, [9] [10] [11] [12] [13] especially for chemotherapy. Thousands of clinical trials have reported that chemotherapy has achieved very satisfied efficacy. [14] [15] [16] However, it also accompanies lots of severe adverse events (AEs), such as nausea and vomiting, fatigue, loss of appetite, pain, diarrhea, and so on. [17] [18] [19] If these AEs cannot be treated fairly and timely, it may affect CC cure by reducing the dosage of chemotherapy, or even quit the chemotherapy. Thus, alternative interventions with fewer adverse reactions are urgently needed to treat those conditions caused by chemotherapy.
Fortunately, numerous clinical trials have reported that electrical stimulation (ES) can be used to treat AEs caused by chemotherapy effectively and safely. [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] However, up to date, no systematic review has systematically investigated the effectiveness and safety of ES for AEs result from chemotherapy in patients with CC. Therefore, in this systematic review, we aim to assess the effectiveness and safety of ES for AEs caused by chemotherapy in patients with CC.
Methods and analysis

Study registration
The reports of this systematic review protocol have followed the Preferred Reporting Items for Systematic Reviews and Meta-Analysis Protocol statement guidelines. [34] It has been registered on PROSPERO (CRD42019120191). Table 1 . Any other databases and sources will also be retrieved by using the similar search strategy. 
Study selection.
Two reviewers will independently select the potential studies based on the predefined eligibility criteria. All the study selection process will be performed according to the PRISMA flowchart, and is presented in Figure 1 . Any disagreements will be solved by consulting a third reviewer through discussion.
Data collection.
After selection, all the related data will be extracted from the included studies by using predefined data extraction forms. Two independent reviewers will carry out the data extraction. Any divergences of data extraction will be settled down by a third reviewer invited through discussion. The forms consist of the following information. General information: title, first author, publication year, country, eligibility criteria, and patient characteristics.
Study methods: sample size, randomization, concealment, blinding, and any other potential risk of bias.
Intervention details: dosage, frequency, duration. Outcomes: primary, secondary, and safety outcome measurements.
2.3.4.
Dealing with essential missing information. Any essential missing information, including missing data, will be inquired by contracting original authors to request. We will pool the available data only if the missing data cannot be achieved.
Risk of bias assessment
In this study, we will apply Cochrane risk of bias tool to assess the methodology quality for each included study. All the procedures will be performed by 2 independent reviewers. Disagreements between 2 reviewers will be resolved by a third review through discussion.
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, and pooled will be pooled by using a fixed-effect model. The significant heterogeneity will be considered if I 2 >50%, and data will be pooled by using a random-effect model. Under such situation, subgroup analysis will be conducted. If there is still significant heterogeneity after the subgroup analysis, we will not pool the data, and carry out the meta-analysis. Instead, we will just report results as narrative description.
2.6. Additional analysis 2.6.1. Subgroup analysis. Subgroup analysis will be carried out if the heterogeneity is substantial. It will be conducted according to different locations, study quality, treatment types, treatment duration, and outcome tools.
2.6.2. Sensitivity analysis. Sensitivity analysis will be carried out to ensure the robustness and stability of pooled results data by removing low-quality trials.
2.6.3. Reporting bias. If sufficient eligible studies are included, the potential reporting bias will be identified by funnel plots. [35] Additionally, Egg regression test will also be performed to check the asymmetry of funnel plots. [36] 
Discussion
To our best knowledge, although lots of clinical trials regarding the effectiveness of ES on AEs caused by chemotherapy in patients with CC were conducted, [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] no systematic review specifically focused on the ES for AEs caused by chemotherapy in patients with CC. Therefore, the purpose of this study is to evaluate the effectiveness of ES on different AEs resulted from chemotherapy on CC. The results of this study will provide most present evidence on the effectiveness of ES for the treatment of AEs caused by chemotherapy in patients with CC. Its findings may also provide helpful evidence for the clinical practice, and researchers for further study.
